NCT05949268 Video Capsule Endoscopy for Detection of Gastrointestinal Bleeding in the Small Bowel
| NCT ID | NCT05949268 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Freiburg |
| Condition | GastroIntestinal Bleeding |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,300 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,300 participants in total. It began in 2023-09-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Small bowel capsule endoscopy is the main diagnostic standard for small bowel bleeding. This study investigates the detection rate of small bowel bleeding in capsule endoscopy and further endoscopic treatment in a prospective and retrospective cohort.
Eligibility Criteria
Inclusion Criteria: * suspicion of gastrointestinal bleeding in the small bowel undetected by gastroscopy and colonoscopy * informed consent Exclusion Criteria: * contraindications for small bowel capsule endoscopy (e.g. stenosis)
Contact & Investigator
Michael Schultheiss, MD
PRINCIPAL INVESTIGATOR
University Medical Center Freiburg, Department of Medicine II, Freiburg, Germany
Frequently Asked Questions
Who can join the NCT05949268 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying GastroIntestinal Bleeding. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05949268 currently recruiting?
Yes, NCT05949268 is actively recruiting participants. Contact the research team at michael.schultheiss@uniklinik-freiburg.de for enrollment information.
Where is the NCT05949268 trial being conducted?
This trial is being conducted at Freiburg im Breisgau, Germany.
Who is sponsoring the NCT05949268 clinical trial?
NCT05949268 is sponsored by University Hospital Freiburg. The principal investigator is Michael Schultheiss, MD at University Medical Center Freiburg, Department of Medicine II, Freiburg, Germany. The trial plans to enroll 1,300 participants.